Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods
Marieke Henstra(Amsterdam University Medical Centers), Didi Rhebergen(GGz centraal), Nathalie van der Velde(GGD Amsterdam), Mardien L. Oudega(GGZ inGeest), Judith E. Bosmans(Amsterdam Public Health), Max L. Stek(GGZ inGeest), Annemiek Dols(Utrecht University), Simon Lambrichts(KU Leuven), Merijn Eikelenboom(University of Amsterdam), Rob Kok(Parnassia Groep), Thomas C. Feenstra, Harm‐Pieter Spaans(Parnassia Groep), Adriano van der Loo(OLVG), Pierre M. Bet, Stephan A. Loer(Amsterdam University Medical Centers), Aartjan T.F. Beekman(Amsterdam Neuroscience), Pascal Sienaert(Huntsman (Belgium)), Filip Bouckaert(Allen Institute for Brain Science), A. C. M. Vergouwen(OLVG), Eric van Exel(Amsterdam Neuroscience)
Cited by 6
Related Papers
World guidelines for falls prevention and management for older adults: a global initiative
|Age and Ageing|2022|1.5k
Evaluation of Clinical Practice Guidelines on Fall Prevention and Management for Older Adults
|JAMA Network Open|2021|330
Gene expression in major depressive disorder
|Molecular Psychiatry|2015|235
The Genetics of the Mood Disorder Spectrum: Genome-wide Association Analyses of More Than 185,000 Cases and 439,000 Controls
|Biological Psychiatry|2019|212
The Genetic Architecture of Depression in Individuals of East Asian Ancestry
|JAMA Psychiatry|2021|204